Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. The poster will be made available on the Sensei Bio website following the presentation.
SENSEI BIOTHERAPEUTICS FULL
The full abstract will be available online as a supplement to the AACR journal, Cancer Immunology Research. Title: SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsivenessĭate and Time: Friday, September 30, from 12:15 pm-2:15 pm ET. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 28 – Octoat the New York Hilton Midtown in New York, New York. 21, 2022 (GLOBE NEWSWIRE) - Sensei Biotherapeutics, Inc. GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return.Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into SurvivalīOSTON, Sept. 2022, Sensei Biotherapeutics's latest two-year average Short-Term Debt & Capital Lease Obligation was €0.31405200000625 Mil and its latest two-year average Long-Term Debt & Capital Lease Obligation was €1.0091280000087 Mil. It is simplified by adding the latest two-year average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. As of today, Sensei Biotherapeutics's market capitalization (E) is €52.505 Mil. The market value of equity (E) is also called " Market Cap". We need to calculate the weight of equity and the weight of debt. Generally speaking, a company's assets are financed by debt and equity. Payments to Suppliers for Goods and Services.Other Cash Receipts from Operating Activities.Other Cash Payments from Operating Activities.Cash Received from Insurance Activities.Cash Receipts from Securities Related Activities.Cash Receipts from Operating Activities.
Cash Receipts from Fees and Commissions.Cash Receipts from Deposits by Banks and Customers.Cash Payments for Deposits by Banks and Customers.Cash from Discontinued Operating Activities.Cash From Discontinued Investing Activities.Short-Term Debt & Capital Lease Obligation.Other Liabilities for Insurance Companies.Long-Term Debt & Capital Lease Obligation.Inventories, Raw Materials & Components.Cash, Cash Equivalents, Marketable Securities.
0 kommentar(er)
